Alicia Morgans: Hi. I’m thrilled to have here with me today Dr. Cora Sternberg, who’s a medical oncologist and the Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell. Thank you so much for being here. Cora Sternberg: It’s a pleasure. Alicia Morgans: Wonderful. So I wanted to talk with you about […]
Charles Ryan: Hello. I’m Charles Ryan from the University of Minnesota. Today we’re going to have a panel discussion about the upcoming APCCC meeting, a very important conference in our field thanks to the works of Silke Gillessen from St. Gallen and Manchester University and Aurelius Omlin, also from St. Gallen. So, I’m delighted that the […]
Diane Newman: Welcome. I’m Diane Newman. I’m a nurse practitioner and Adjunct Professor of Urology and Surgery at the University of Pennsylvania, and I’m Editor of the UroToday Pelvic Health Center. Today I’m very happy to introduce my guest, Tessa Huang. She is from Mainland China. I recently met Tessa when I was teaching in […]
Jaime Landman: It’s Jaime Landman from the EAU 2019 in beautiful Barcelona. And today I have the great privilege of being with a close friend, colleague and a partner from UCI, Dr. Thomas Ahlering. TA is the Vice Chair, a world-renowned recognized leader in prostate cancer. And I think he shocked me here at the […]
Small cell bladder cancers (SCCB) are a relatively rare, but highly aggressive disease.1 Given the lack of randomized prospective trials, retrospective studies and few prospective series support the treatment decisions. A multimodality approach, which combines chemotherapy with radiation or surgery, is often proposed to patients with localized disease. The use of chemotherapy has been associated with […]
While bladder cancer is less common among women, female sex is associated with worse oncological outcomes. To evaluate sex-specific differences in initial presentation and treatment patterns of muscle-invasive bladder cancer. A retrospective study using the National Cancer Database to identify individuals diagnosed with muscle-invasive bladder cancer (cT2-T4aN0M0) between 2004 and 2013. Multivariable logistic regression and […]
In patients with bladder cancer, poor functional status has remarkable deleterious effects on postoperative outcome and prognosis. Conditioning intervention initiated before surgery has the potential to reduce functional decline attributable to surgery. Nonetheless, evidence is lacking in patients undergoing radical cystectomy. To determine whether a preoperative multimodal intervention (prehabilitation) is feasible and effective in radical […]
Dysregulation of the extracellular matrix molecule biglycan (BGN) predicts poor survival in several cancer entities. Our study investigated the prognostic impact of BGN in bladder cancer (BC) in 2 independent cohorts and assessed its role in epithelial-mesenchymal transition (EMT) and association with molecular BC subtypes. BGN protein expression was correlated with the oncological outcome of […]
The “super-active surveillance” concept denotes any active surveillance optimization that allows longer surveillance periods, with the main intention of avoiding overtreatment, by safely eliminating or postponing radical treatment. Super-active surveillance might add to the oncological control with minimal functional impact and similar quality of life compared to active surveillance, which has proved to be safe […]
Signaling via the Src pathway is thought to be a mediator of resistance to androgen targeted therapy in prostate cancer. We studied whether adding the Src inhibitor dasatinib to abiraterone would delay progression. Eligible patients had metastatic castration-resistant prostate cancer (mCRPC), without prior chemotherapy. Abiraterone was prescribed at 1000 mg daily with prednisone 5 mg […]
